Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $255.11 USD
Change Today -0.26 / -0.10%
Volume 308.6K
SHPG On Other Exchanges
Symbol
Exchange
SHPG is not on other exchanges.
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Riverwalk

Citywest Business Campus

Dublin, 24

Ireland

Phone: 353 1 429 7700

Fax:

reatment of patients with Hunter syndrome. ELAPRASE has been granted orphan drug exclusivity by both the FDA and the EMA. As of December 31, 2014, ELAPRASE was approved in 51 countries. VPRIV VPRIV is a treatment for Type 1 Gaucher disease. Gaucher disease is a rare, inherited genetic disorder, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. This enzymatic deficiency causes an accumulation of glucocerebroside, primarily in macrophages called Gaucher cells in the liver, spleen, bone marrow, and other organs. The accumulation of glucocerebrosidase in Gaucher cells in the liver and spleen leads to organomegaly. VPRIV was approved by the FDA in 2010 for the long term treatment of patients with Type 1 Gaucher disease. As of December 31, 2014, VPRIV was approved in 40 countries. FIRAZYR FIRAZYR is a peptide-based therapeutic developed for the symptomatic treatment of acute attacks of hereditary angioedema (HAE). HAE is a debilitating and potentially life-threatening genetic disease characterized by unpredictable recurring swelling attacks in the hands, feet, face, larynx, or abdomen. As of December 31, 2014, FIRAZYR was approved in 38 countries. CINRYZE CINRYZE is a C1 esterase inhibitor therapy for routine prophylaxis against HAE, also known as C1 inhibitor (C1-INH) deficiency. CINRYZE is marketed and sold in the United States for routine prophylaxis against HAE attacks in adolescent and adult patients with HAE. As of December 31, 2014, CINRYZE was approved in 36 countries. Treatments for Other Therapeutic Areas FOSRENOL FOSRENOL is a phosphate binder that is indicated for use in patients with end-stage renal disease (stage 5) receiving dialysis and is also indicated in the EU for the treatment of adult patients with chronic kidney disease (CKD) who are not on dialysis with serum phosphate > 1.78 mmol/L (5.5 mg/dL) in which a low phosphate diet alone is insufficient to control serum phosphate levels. FOSRENOL binds dietary phosphate in the gastrointestinal tract to prevent it from passing through the gut lining and, based upon this mechanism of action, phosphate absorption from the diet is decreased. As of December 31, 2014, FOSRENOL was approved in 48 countries. XAGRID/AGRYLIN XAGRID is an orphan medicinal product, which is marketed in Europe for the reduction of elevated platelet counts in at-risk ET patients. In the United States, anagrelide hydrochloride is sold by the company under the trade name AGRYLIN for the treatment of thrombocythemia secondary to a MPD. As of December 31, 2014, XAGRID/AGRYLIN was approved in 47 countries. PLENADREN Adrenal insufficiency (AI) is a rare, chronic and potentially fatal endocrine disorder characterised by failure in the production of the hormone cortisol. AI affects approximately 4.5 in 10,000 people in Europe, but can lead to serious, life-threatening conditions, such as cardiovascular, malignant or infectious diseases, as well as disorders which impact on health and quality of life. The many symptoms of AI include fatigue, anorexia, weight-loss, fever, muscle weakness, abdominal pains, dizziness and headaches. To survive, AI patients need replacement therapy with glucocorticoids (usually hydrocortisone) and because it is a chronic condition, they require this life-saving therapy throughout their lives. PLENADREN is indicated for the treatment of adrenal insufficiency in adults. It is a novel, once daily hydrocortisone, dual-release tablet, designed to better mimic the body's natural cortisol production compared to standard treatment. PLENADREN is proven to be effective and well tolerated compared to standard therapy, demonstrating a delivery of cortisol that is more in line with the body's own cortisol profile, thus avoiding the unphysiological cortisol peaks seen with standard glucocorticoid therapy. These peaks are thought to be associated with an increased risk of morbidity and premature mortality. Royalties Received from Other Products Antiviral Products The company receives royalties on antiviral products based on certain of its patents licensed to GlaxoSmithKline. These antiviral products are fo

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPG:US $255.11 USD -0.26

SHPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CSL Ltd A$95.21 AUD +1.39
Eisai Co Ltd ¥8,132 JPY -104.00
Hospira Inc $87.61 USD -0.05
Mylan NV $76.06 USD +2.37
UCB SA €69.02 EUR +0.03
View Industry Companies
 

Industry Analysis

SHPG

Industry Average

Valuation SHPG Industry Range
Price/Earnings 15.4x
Price/Sales 8.3x
Price/Book 5.8x
Price/Cash Flow 14.8x
TEV/Sales 8.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.